MegaPro Biomedical Co., Ltd
MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs. It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as well as MPB-1734, an anti-cancer drug that is in precl… Read more
MegaPro Biomedical Co., Ltd (6827) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.368x
Based on the latest financial reports, MegaPro Biomedical Co., Ltd (6827) has a cash flow conversion efficiency ratio of -0.368x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-48.98 Million) by net assets (NT$132.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
MegaPro Biomedical Co., Ltd - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how MegaPro Biomedical Co., Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
MegaPro Biomedical Co., Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MegaPro Biomedical Co., Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Han Chang Paper Co. Ltd.
KQ:009460
|
N/A |
|
Sunrays Textile Mills Ltd
KAR:SUTM
|
N/A |
|
Tinybuild Inc
LSE:TBLD
|
0.164x |
|
MORNING LIGHT LTD
SEM:MOLI
|
N/A |
|
PetroVietnam Oil Phu Yen JSC
VN:PPY
|
N/A |
|
Zovio Inc
PINK:ZVOI
|
-5.153x |
|
Service Global
KAR:SGF
|
N/A |
|
Biafo Industries Ltd
KAR:BIFO
|
N/A |
Annual Cash Flow Conversion Efficiency for MegaPro Biomedical Co., Ltd (2020–2024)
The table below shows the annual cash flow conversion efficiency of MegaPro Biomedical Co., Ltd from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$204.35 Million | NT$-144.17 Million | -0.705x | -90.40% |
| 2023-12-31 | NT$269.07 Million | NT$-99.70 Million | -0.371x | -40.67% |
| 2022-12-31 | NT$314.35 Million | NT$-82.80 Million | -0.263x | -25.72% |
| 2021-12-31 | NT$405.84 Million | NT$-85.03 Million | -0.210x | +66.97% |
| 2020-12-31 | NT$246.37 Million | NT$-156.30 Million | -0.634x | -- |